Hepatic impairment No dose adjustment is needed in people with gentle or moderate (Little one-Pugh A or B) hepatic impairment (see portion five.2). Exposure to midostaurin and its active metabolite CGP62221 is significantly reduce in patients with significant hepatic impairment than that in people with typical hepatic purpose (see segment https://charlesj207zfi1.wikipublicity.com/user